Released Nov 8, 2018, after the close
10-Q filed Nov 8, 2018, 39 days after period end · 0001564590-18-028526
Q3 2018 · 10-Q
Revenue$658.00K$658.00K +10.2% vs Q3 2017+42.1% vs Q2 2018
Net Income-$10.46M-$10.46M N/M vs Q3 2017N/M vs Q2 2018
EPS Diluted-$0.60-$0.60 N/M vs Q3 2017N/M vs Q2 2018
Operating Income-$10,935,000N/M
Operating Cash Flowderived-$5,514,000N/M
Margins · derived
Operating margin-1661.9%+7.5 pt vs Q3 2017
Net margin-1590.1%+57.4 pt vs Q3 2017
What the release said
The release
Same quarter
| Metric | Q3 2018 | Q3 2017 | Q3 2016 |
|---|---|---|---|
| Revenue | $658.00K | $597.00K | — |
| Net Income | -$10.46M | -$9.84M | -$6.32M |
| EPS Diluted | -$0.60 | -$36.02 | -$23.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR